Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-03-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于拟聘请会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company about the proposed appointment of an accounting firm (auditor) for the upcoming fiscal year 2024. It details the qualifications, experience, and independence of the proposed auditor, the approval process by the board and audit committee, and the need for shareholder approval. It does not contain any actual financial statements or audit reports but rather is a formal announcement regarding the auditor appointment. The document length is 3823 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement related to audit matters but not the audit report itself.
2024-03-29 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 5th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes approvals of the 2023 annual report, audited financial statements, profit distribution plan, appointment of auditors, changes in board committees, amendments to governance documents, and other corporate governance matters. The document references submission of these reports and proposals to the 2023 Annual General Meeting for approval and provides links to the full reports on an external site (巨潮资讯网). The document is not the annual report itself but a board meeting resolution announcement covering multiple governance and financial reporting topics. It is a formal disclosure of board decisions rather than a full financial report or earnings release. Therefore, it fits best under Board/Management Information (MANG) as it primarily announces board meeting resolutions and governance changes. The document length (7889 characters) and content support this classification with high confidence.
2024-03-29 Chinese
关于举办2023年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the holding of a 2023 annual performance online briefing by the company Yunnan Watson Biotechnology Co., Ltd. It references that the 2023 annual report has already been disclosed on March 30, 2024, and the briefing is scheduled for April 3, 2024. The document provides details about the time, place, participants, and how investors can join the online meeting. It does not contain the actual annual report or detailed financial data but rather announces an event related to discussing the annual report. The document length is short (991 characters), and it is clearly an announcement of a meeting to explain the annual results, not the report itself or a transcript of the meeting. Therefore, it fits best into the category of Investor Presentation (IP) since it is a detailed presentation event for investors focusing on financials and company strategy, or possibly AGM Information (AGM-R) if it were an AGM. However, since it is specifically an annual performance briefing (earnings explanation meeting) and not an AGM, the best fit is Investor Presentation (IP).
2024-03-29 Chinese
2023年度独立董事述职报告（孙钢宏）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of a company for the year 2023. It includes descriptions of the director's duties, attendance at board meetings, independent opinions on various company matters, communication with auditors, and other governance-related activities. The content focuses on the independent director's role and responsibilities, including oversight of internal controls, financial audits, and corporate governance. It does not contain financial statements or quarterly/annual financial results but rather a narrative on the director's activities and opinions. This type of document aligns with a Management Report or a Director's Report on their duties and oversight, which fits best under the category 'Board/Management Information (MANG)'. The document length (7268 characters) and detailed content confirm it is a full report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2024-03-29 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (special audit report) related to the company's non-operating fund occupation and other related party fund transactions for the year 2023. It is issued by a certified public accounting firm and includes audit opinions, responsibilities of management and governance, and detailed financial data tables. The document is not a full annual report but a standalone audit report focusing on a specific financial aspect. It contains substantive financial data and audit conclusions, which fits the definition of an Audit Report / Information (AR). The document length is 3502 characters, which is sufficient for a detailed audit report but not a brief announcement. Therefore, the classification is AR with high confidence. FY 2023
2024-03-29 Chinese
2023年度独立董事述职报告（朱锦余）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2023 from a specific independent director of the company. It details the director's activities, attendance at board meetings, opinions on various company matters, communication with auditors, and compliance with laws and regulations. The content focuses on the director's duties, governance, and oversight rather than financial results or earnings. It is a detailed report on board/management activities and governance oversight rather than a financial report or announcement. Therefore, it fits best under the category of Board/Management Information (MANG). The document length and detail confirm it is a full report, not a brief announcement or certification.
2024-03-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.